Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200)
Cerus Corporation (Nasdaq: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood System for platelets and plasma under the European Union (EU) Medical Device Regulation (MDR). This approval allows Cerus to market the INT200 throughout the EU and in other regions that recognize the CE mark. Some countries may require additional in-country regulatory approval prior to commercialization. With the receipt of CE mark approvals of the INTERCEPT processing sets for platelets and plasma under the MDR in 2023, today’s announced approval completes the authorization of the INTERCEPT Blood System for both platelets and plasma within the EU MDR framework.
Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results
Cerus Corporation (Nasdaq: CERS) today announced financial results for its full year and fourth quarter ended December 31, 2024.
Cerus Corporation to Participate in the TD Cowen 45th Annual Health Care Conference
Cerus Corporation (Nasdaq: CERS) announced today that members of Cerus’ management are scheduled to present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 11:10 a.m. EST.
Cerus Corporation to Release Fourth Quarter and Full-Year 2024 Financial Results on February 20, 2025
Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2024 financial results will be released on Thursday, February 20, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update
Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2024 and provided product revenue guidance for full-year 2025.
Cerus Corporation to Participate in Upcoming Investor Conferences
Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences.
Cerus Corporation Announces Third Quarter 2024 Financial Results
Cerus Corporation (Nasdaq: CERS) today announced financial results for its third quarter and nine months ended September 30, 2024.
Cerus Corporation to Release Third Quarter 2024 Financial Results on October 30, 2024
Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2024 financial results will be released on Wednesday, October 30, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting
Cerus Corporation (Nasdaq: CERS) today announced a selection of abstracts to be presented at the 2024 Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting, taking place in Houston, Texas from October 19 through October 22. This year’s AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies.
Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe
Cerus Corporation (Nasdaq:CERS) today announced updates on the INTERCEPT red blood cell (RBC) programs in the U.S. and in Europe:
Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range
Cerus Corporation (Nasdaq: CERS) today announced financial results for its second quarter and six months ended June 30, 2024.
Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024
Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
